The stock of Seelos Therapeutics Inc. (NASDAQ:SEEL) increased by $0.17 on Tuesday to finish at $1.00, up 19.76 percent. The last five days have seen an average of 996,640 shares of common stock traded. 23 times new highs were reached in the current year, with a gain of $0.3210. The average number of shares traded over the last 20 days was 818,295, while the average volume over the last 50 days totaled 976,402.
SEEL stock dropped -10.71% since last month. On 09/18/23, the company’s shares reached a one-month low of $0.8226. The stock touched a high of $1.66 on 08/03/23, after rallying from a low of $0.58 in 52 weeks. The price of SEEL stock has risen by 47.28% or $0.3210 this year, reaching a new high 23 times. Still, the stock price is down -39.76% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Financial Health
For the three months ended June 29, Seelos Therapeutics Inc.’s quick ratio was 0.20, while its current ratio was 0.20, indicating its inability to pay off its debt. Based on annual data, it had gross profit of $70.92 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. SEEL’s return on assets (ROA) during the last 12 months has been -328.70%. In the meantime, the return on equity (ROE) for the last 12 months was 460.20%.
Earnings Surprise
According to Seelos Therapeutics Inc.’s quarterly financial report for the quarter that ended June 29. A lower net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $0.42 million, while revenues rose by 95.24% to $0.88 million. It was predicted that Seelos Therapeutics Inc.’s quarterly earnings would be -$0.22, but it ended up being -$0.09, beating the consensus by -144.40%. EBITDA was -$10.94 million for the quarter. At the end of Seelos Therapeutics Inc.’s most recent quarter ended June 29, its liabilities totaled 59.07 million, while its total debt was $15.34 million. Equity owned by shareholders amounts to $127.36 million.
Technical Picture
Here’s a quick look at Seelos Therapeutics Inc.’s (SEEL) price momentum from a technical perspective. As of 19 September, the RSI 9-day stood at 48.75%, suggesting the stock is Neutral, with a 117.98% historical volatility rate.
The stochastic %K and %D were 17.22% and 9.39% respectively, while the average true range (ATR) was 0.0932. Based on the 14-day stochastic reading of 45.21%, the RSI (14) reading is 44.45%. On the 9-day MACD Oscillator, the stock is at -0.0335, and the 14-day reading is at -0.0692.
Analyst Ratings
In its most recent analyst report, ROTH Capital raised its rating on Seelos Therapeutics Inc. (NASDAQ: SEEL) to a Buy. Prior to this, analysts firm rated the stock as a Neutral. Analysts have assigned Seelos Therapeutics Inc. (SEEL) an Buy rating. SEEL is a stock that is recommended for selling by 0 brokerage firms, while 0 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 3 others recommend it as a buy.
What is SEEL’s price target for the next 12 months?
The current consensus forecast for the stock is between $2.00 and $4.00, with a median target price of $4.00. In analyzing these forecasts, the average price target given by analysts for Seelos Therapeutics Inc. (SEEL) is $3.33.
